Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients

Background Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0‐17 years). Methods A physician‐based...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric allergy and immunology Vol. 29; no. 6; pp. 630 - 636
Main Authors: Balp, Maria‐Magdalena, Weller, Karsten, Carboni, Veruska, Chirilov, Alexandra, Papavassilis, Charis, Severin, Thomas, Tian, Haijun, Zuberbier, Torsten, Maurer, Marcus
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01.09.2018
Subjects:
ISSN:0905-6157, 1399-3038, 1399-3038
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Background Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0‐17 years). Methods A physician‐based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population. Results are based on physician responses and analyzed using descriptive statistics. Prevalence estimates were calculated based on the number of CU/CSU pediatric patients diagnosed, seen, and treated by the respondents and extrapolated to the total pediatric population from each country. Results Across 5 European countries, the one‐year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94‐1.86) and 0.75% (95% CI, 0.44‐1.08), respectively. Angioedema was reported in 6%‐14% of patients. A large proportion of CSU pediatric patients (40%‐60%) were treated with H1‐antihistamines at approved dose and 16%‐51% received H1‐antihistamines at higher doses. Approximately 1/3 of pediatric CSU patients remained uncontrolled with H1‐antihistamines at approved/higher doses. Other prescribed treatments were oral corticosteroids (10%‐28%) and topical creams (15%‐26%). Conclusions This study revealed a prevalence of CSU among pediatric population comparable to adults and also suggested an unmet need for approved treatments for inadequately controlled pediatric CSU patients. It is truly of concern that harmful (oral steroids) or insufficient (topical creams) treatments were frequently used despite better and guideline‐recommended alternatives.
AbstractList Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0-17 years). A physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population. Results are based on physician responses and analyzed using descriptive statistics. Prevalence estimates were calculated based on the number of CU/CSU pediatric patients diagnosed, seen, and treated by the respondents and extrapolated to the total pediatric population from each country. Across 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively. Angioedema was reported in 6%-14% of patients. A large proportion of CSU pediatric patients (40%-60%) were treated with H1-antihistamines at approved dose and 16%-51% received H1-antihistamines at higher doses. Approximately 1/3 of pediatric CSU patients remained uncontrolled with H1-antihistamines at approved/higher doses. Other prescribed treatments were oral corticosteroids (10%-28%) and topical creams (15%-26%). This study revealed a prevalence of CSU among pediatric population comparable to adults and also suggested an unmet need for approved treatments for inadequately controlled pediatric CSU patients. It is truly of concern that harmful (oral steroids) or insufficient (topical creams) treatments were frequently used despite better and guideline-recommended alternatives.
Background Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0‐17 years). Methods A physician‐based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population. Results are based on physician responses and analyzed using descriptive statistics. Prevalence estimates were calculated based on the number of CU/CSU pediatric patients diagnosed, seen, and treated by the respondents and extrapolated to the total pediatric population from each country. Results Across 5 European countries, the one‐year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94‐1.86) and 0.75% (95% CI, 0.44‐1.08), respectively. Angioedema was reported in 6%‐14% of patients. A large proportion of CSU pediatric patients (40%‐60%) were treated with H1‐antihistamines at approved dose and 16%‐51% received H1‐antihistamines at higher doses. Approximately 1/3 of pediatric CSU patients remained uncontrolled with H1‐antihistamines at approved/higher doses. Other prescribed treatments were oral corticosteroids (10%‐28%) and topical creams (15%‐26%). Conclusions This study revealed a prevalence of CSU among pediatric population comparable to adults and also suggested an unmet need for approved treatments for inadequately controlled pediatric CSU patients. It is truly of concern that harmful (oral steroids) or insufficient (topical creams) treatments were frequently used despite better and guideline‐recommended alternatives.
Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0-17 years).BACKGROUNDData on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0-17 years).A physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population. Results are based on physician responses and analyzed using descriptive statistics. Prevalence estimates were calculated based on the number of CU/CSU pediatric patients diagnosed, seen, and treated by the respondents and extrapolated to the total pediatric population from each country.METHODSA physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population. Results are based on physician responses and analyzed using descriptive statistics. Prevalence estimates were calculated based on the number of CU/CSU pediatric patients diagnosed, seen, and treated by the respondents and extrapolated to the total pediatric population from each country.Across 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively. Angioedema was reported in 6%-14% of patients. A large proportion of CSU pediatric patients (40%-60%) were treated with H1-antihistamines at approved dose and 16%-51% received H1-antihistamines at higher doses. Approximately 1/3 of pediatric CSU patients remained uncontrolled with H1-antihistamines at approved/higher doses. Other prescribed treatments were oral corticosteroids (10%-28%) and topical creams (15%-26%).RESULTSAcross 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively. Angioedema was reported in 6%-14% of patients. A large proportion of CSU pediatric patients (40%-60%) were treated with H1-antihistamines at approved dose and 16%-51% received H1-antihistamines at higher doses. Approximately 1/3 of pediatric CSU patients remained uncontrolled with H1-antihistamines at approved/higher doses. Other prescribed treatments were oral corticosteroids (10%-28%) and topical creams (15%-26%).This study revealed a prevalence of CSU among pediatric population comparable to adults and also suggested an unmet need for approved treatments for inadequately controlled pediatric CSU patients. It is truly of concern that harmful (oral steroids) or insufficient (topical creams) treatments were frequently used despite better and guideline-recommended alternatives.CONCLUSIONSThis study revealed a prevalence of CSU among pediatric population comparable to adults and also suggested an unmet need for approved treatments for inadequately controlled pediatric CSU patients. It is truly of concern that harmful (oral steroids) or insufficient (topical creams) treatments were frequently used despite better and guideline-recommended alternatives.
BackgroundData on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This study assessed the prevalence of CU and CSU, and disease management among pediatric patients (0‐17 years).MethodsA physician‐based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population. Results are based on physician responses and analyzed using descriptive statistics. Prevalence estimates were calculated based on the number of CU/CSU pediatric patients diagnosed, seen, and treated by the respondents and extrapolated to the total pediatric population from each country.ResultsAcross 5 European countries, the one‐year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94‐1.86) and 0.75% (95% CI, 0.44‐1.08), respectively. Angioedema was reported in 6%‐14% of patients. A large proportion of CSU pediatric patients (40%‐60%) were treated with H1‐antihistamines at approved dose and 16%‐51% received H1‐antihistamines at higher doses. Approximately 1/3 of pediatric CSU patients remained uncontrolled with H1‐antihistamines at approved/higher doses. Other prescribed treatments were oral corticosteroids (10%‐28%) and topical creams (15%‐26%).ConclusionsThis study revealed a prevalence of CSU among pediatric population comparable to adults and also suggested an unmet need for approved treatments for inadequately controlled pediatric CSU patients. It is truly of concern that harmful (oral steroids) or insufficient (topical creams) treatments were frequently used despite better and guideline‐recommended alternatives.
Author Balp, Maria‐Magdalena
Weller, Karsten
Chirilov, Alexandra
Severin, Thomas
Zuberbier, Torsten
Papavassilis, Charis
Maurer, Marcus
Carboni, Veruska
Tian, Haijun
Author_xml – sequence: 1
  givenname: Maria‐Magdalena
  orcidid: 0000-0002-8612-7680
  surname: Balp
  fullname: Balp, Maria‐Magdalena
  email: maria-magdalena.balp@novartis.com
  organization: Novartis Pharma AG
– sequence: 2
  givenname: Karsten
  surname: Weller
  fullname: Weller, Karsten
  organization: Charité ‐ Universitätsmedizin Berlin
– sequence: 3
  givenname: Veruska
  surname: Carboni
  fullname: Carboni, Veruska
  organization: GfK Switzerland AG
– sequence: 4
  givenname: Alexandra
  surname: Chirilov
  fullname: Chirilov, Alexandra
  organization: GfK SE
– sequence: 5
  givenname: Charis
  surname: Papavassilis
  fullname: Papavassilis, Charis
  organization: Novartis Pharma AG
– sequence: 6
  givenname: Thomas
  surname: Severin
  fullname: Severin, Thomas
  organization: Novartis Pharma AG
– sequence: 7
  givenname: Haijun
  surname: Tian
  fullname: Tian, Haijun
  organization: Novartis Pharmaceuticals Corporation
– sequence: 8
  givenname: Torsten
  surname: Zuberbier
  fullname: Zuberbier, Torsten
  organization: Charité ‐ Universitätsmedizin Berlin
– sequence: 9
  givenname: Marcus
  surname: Maurer
  fullname: Maurer, Marcus
  organization: Charité ‐ Universitätsmedizin Berlin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29679413$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1LAzEQhoMo2lYP_gEJeNHDtvnY3WyOUvyCgj3o1RCzE4xss2uyq_jvTW17ER0CGTLP-zKZGaN933pA6JSSKU0x67SbUiYp2UMjyqXMOOHVPhoRSYqspIU4QuMY3wihgpf0EB0xWQqZUz5Cz8sAH7oBbwBrX2PTOO-MbrB51UGbHoKLvTMRtzY9hTYVcexa32sP7RDxEFJVB6ex87iD2uk-JKTTvQPfx2N0YHUT4WR7T9DTzfXj_C5bPNzez68WmcmLnGS0LKWlwppKMM0KIWqR16KSRDDLq9xakxsDpGDmhQkBFVQWBNcyBc3X6QRdbHy70L4PEHu1ctFA02zaVIywSuYlT2eCzn-hb-0QfOouUTINixOyNjzbUsPLCmrVBbfS4UvtJpeA2QYwoY0xgFXG9enXaTRBu0ZRota7UWk36mc3SXH5S7Ez_Yvdun-6Br7-B9Xy6n6j-AZM8Z1a
CitedBy_id crossref_primary_10_1136_bmjopen_2020_045027
crossref_primary_10_3390_biomedicines11041096
crossref_primary_10_1111_pai_13982
crossref_primary_10_3390_jcm13133990
crossref_primary_10_1111_pai_70132
crossref_primary_10_1111_ddg_14727
crossref_primary_10_1016_j_jaip_2024_04_027
crossref_primary_10_1016_j_arcped_2023_01_010
crossref_primary_10_1097_CM9_0000000000002172
crossref_primary_10_1007_s40521_025_00391_2
crossref_primary_10_33590_emj_19_00162
crossref_primary_10_1080_14712598_2024_2354380
crossref_primary_10_1155_2018_5615109
crossref_primary_10_1111_pai_70174
crossref_primary_10_1111_jdv_19940
crossref_primary_10_1016_j_jaip_2025_07_021
crossref_primary_10_1186_s13223_024_00931_6
crossref_primary_10_1038_s41572_022_00389_z
crossref_primary_10_1111_jdv_17724
crossref_primary_10_1080_14656566_2020_1830970
crossref_primary_10_1007_s13555_023_01040_9
crossref_primary_10_2147_JAA_S249765
crossref_primary_10_1016_j_cyto_2024_156814
crossref_primary_10_1111_jdv_17131
crossref_primary_10_1007_s12016_022_08952_y
crossref_primary_10_1111_pai_13325
crossref_primary_10_1111_pai_12950
crossref_primary_10_1177_12034754231222415
crossref_primary_10_1111_bjd_19561
crossref_primary_10_7759_cureus_40006
crossref_primary_10_1111_pai_13925
crossref_primary_10_1007_s40272_019_00365_3
crossref_primary_10_1111_ddg_14906
crossref_primary_10_1007_s00608_020_00778_1
crossref_primary_10_1159_000502521
crossref_primary_10_1111_ddg_14727_g
crossref_primary_10_1016_j_jaip_2020_03_030
crossref_primary_10_1016_j_waojou_2021_100546
crossref_primary_10_1007_s40521_019_00223_0
crossref_primary_10_1111_pde_14360
crossref_primary_10_1016_j_waojou_2022_100719
crossref_primary_10_1016_j_jaip_2019_07_021
crossref_primary_10_1111_pai_13674
crossref_primary_10_1111_all_14037
crossref_primary_10_1159_000507218
crossref_primary_10_1007_s00011_024_01869_6
crossref_primary_10_1007_s12325_025_03172_0
crossref_primary_10_1080_1744666X_2024_2388689
crossref_primary_10_1111_ddg_14906_g
crossref_primary_10_1016_j_jaci_2025_05_019
crossref_primary_10_1097_MD_0000000000023301
crossref_primary_10_1016_j_reval_2023_103682
crossref_primary_10_1097_MD_0000000000023226
crossref_primary_10_1016_j_paed_2024_03_001
crossref_primary_10_1016_j_waojou_2021_100533
crossref_primary_10_1016_j_waojou_2021_100610
crossref_primary_10_1186_s13601_019_0299_y
crossref_primary_10_1111_all_15090
crossref_primary_10_1111_1346_8138_17943
Cites_doi 10.1111/jdv.13198
10.1517/14656566.2016.1159298
10.1111/j.1365-2230.2010.03840.x
10.1111/j.1365-2133.2006.07185.x
10.1111/j.1445-5994.2008.01719.x
10.1067/mjd.2001.116217
10.1111/pde.12568
10.1097/ACI.0b013e3283574cb3
10.1111/j.1399-3038.2010.01120.x
10.1111/all.12313
10.1111/j.1365-2133.1981.tb15306.x
10.1001/jamadermatol.2017.3183
10.1164/rccm.2204012
10.1111/j.1398-9995.2010.02496.x
10.4168/aair.2017.9.3.212
10.1016/j.jaci.2004.07.042
10.4168/aair.2017.9.3.189
10.1007/s40257-015-0134-8
10.1111/j.1398-9995.2004.00473.x
ContentType Journal Article
Copyright 2018 The Authors. Published by John Wiley & Sons Ltd.
2018 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd.
Copyright © 2018 John Wiley & Sons A/S
Copyright_xml – notice: 2018 The Authors. Published by John Wiley & Sons Ltd.
– notice: 2018 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd.
– notice: Copyright © 2018 John Wiley & Sons A/S
DBID 24P
AAYXX
CITATION
NPM
7T5
H94
K9.
NAPCQ
7X8
DOI 10.1111/pai.12910
DatabaseName Wiley-Blackwell Open Access Collection
CrossRef
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Open Access Collection
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1399-3038
EndPage 636
ExternalDocumentID 29679413
10_1111_pai_12910
PAI12910
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Novartis Pharma AG
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1OB
1OC
24P
29O
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
A8Z
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
J8S
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
O8X
NPM
7T5
ESTFP
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c4540-1669f17fc872a2577d74d789072f384ffc4cce052cb277e8e8fe73a999914fe73
IEDL.DBID 24P
ISICitedReferencesCount 69
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000442500100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0905-6157
1399-3038
IngestDate Mon Sep 08 04:11:54 EDT 2025
Sat Nov 29 14:43:09 EST 2025
Thu Apr 03 07:04:42 EDT 2025
Sat Nov 29 02:43:39 EST 2025
Tue Nov 18 22:20:09 EST 2025
Wed Jan 22 17:06:00 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords angioedema
prevalence
Europe
treatment patterns
chronic urticaria
chronic spontaneous urticaria
pediatric
Language English
License Attribution-NonCommercial-NoDerivs
2018 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4540-1669f17fc872a2577d74d789072f384ffc4cce052cb277e8e8fe73a999914fe73
Notes Funding information
This study was funded by Novartis Pharma AG.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8612-7680
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpai.12910
PMID 29679413
PQID 2091573007
PQPubID 105695
PageCount 7
ParticipantIDs proquest_miscellaneous_2028946346
proquest_journals_2091573007
pubmed_primary_29679413
crossref_citationtrail_10_1111_pai_12910
crossref_primary_10_1111_pai_12910
wiley_primary_10_1111_pai_12910_PAI12910
PublicationCentury 2000
PublicationDate September 2018
PublicationDateYYYYMMDD 2018-09-01
PublicationDate_xml – month: 09
  year: 2018
  text: September 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Montpellier
PublicationTitle Pediatric allergy and immunology
PublicationTitleAlternate Pediatr Allergy Immunol
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2007; 17
1989; 62
2002; 17
2015; 16
2004; 114
2015; 29
2010; 35
2002; 165
1981; 104
2004; 59
2008; 38
2015; 32
2011; 66
2014; 69
2011; 22
2017
1992; 69
2017; 153
2009; 19
2016; 17
2001; 45
2012; 12
2017; 9
2006; 155
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
Del Cuvillo A (e_1_2_7_9_1) 2007; 17
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
Simons FE (e_1_2_7_27_1) 2002; 17
e_1_2_7_25_1
e_1_2_7_24_1
e_1_2_7_23_1
e_1_2_7_22_1
e_1_2_7_20_1
Quaranta JH (e_1_2_7_21_1) 1989; 62
Volonakis M (e_1_2_7_18_1) 1992; 69
Ferrer M (e_1_2_7_8_1) 2009; 19
29974980 - Pediatr Allergy Immunol. 2018 Sep;29(6):669-670
30054937 - Pediatr Allergy Immunol. 2018 Sep;29(6):670-671
References_xml – volume: 66
  start-page: 317
  year: 2011
  end-page: 330
  article-title: Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report
  publication-title: Allergy
– volume: 62
  start-page: 421
  year: 1989
  end-page: 424
  article-title: The natural history and response to therapy of chronic urticaria and angioedema
  publication-title: Ann Allergy
– volume: 17
  start-page: 437
  year: 2002
  end-page: 464
  article-title: H1‐antihistamines in children
  publication-title: Clin Allergy Immunol
– volume: 9
  start-page: 189
  year: 2017
  end-page: 190
  article-title: Prevalence and causes of childhood urticaria
  publication-title: Allergy Asthma Immunol Res
– volume: 17
  start-page: 28
  issue: Suppl 2
  year: 2007
  end-page: 40
  article-title: Use of antihistamines in pediatrics
  publication-title: J Investig Allergol Clin Immunol
– volume: 19
  start-page: 21
  issue: Suppl 2
  year: 2009
  end-page: 26
  article-title: Epidemiology, healthcare, resources, use and clinical features of different types of urticaria
  publication-title: J Investig Allergol Clin Immunol
– volume: 114
  start-page: 922
  year: 2004
  end-page: 927
  article-title: High prevalence of autoimmune urticaria in children with chronic urticaria
  publication-title: J Allergy Clin Immunol
– volume: 59
  start-page: 869
  year: 2004
  end-page: 873
  article-title: Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients
  publication-title: Allergy
– volume: 22
  start-page: 1
  year: 2011
  end-page: 8
  article-title: Chronic spontaneous urticaria in children: itching for insight
  publication-title: Pediatr Allergy Immunol
– volume: 38
  start-page: 719
  year: 2008
  end-page: 731
  article-title: Are children just small adults? The differences between paediatric and adult sleep medicine
  publication-title: Intern Med J
– volume: 45
  start-page: 387
  year: 2001
  end-page: 391
  article-title: Natural course of physical and chronic urticaria and angioedema in 220 patients
  publication-title: J Am Acad Dermatol
– volume: 153
  start-page: 1221
  year: 2017
  end-page: 1222
  article-title: Chronic urticaria in children – still itching for insight
  publication-title: JAMA Dermatol
– volume: 69
  start-page: 61
  year: 1992
  end-page: 65
  article-title: Etiologic factors in childhood chronic urticaria
  publication-title: Ann Allergy
– volume: 165
  start-page: 1466
  year: 2002
  end-page: 1467
  article-title: Pediatric interstitial lung disease: children are not small adults
  publication-title: Am J Respir Crit Care Med
– volume: 16
  start-page: 313
  year: 2015
  end-page: 321
  article-title: Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria
  publication-title: Am J Clin Dermatol
– volume: 35
  start-page: 869
  year: 2010
  end-page: 873
  article-title: Epidemiology of urticaria: a representative cross‐sectional population survey
  publication-title: Clin Exp Dermatol
– volume: 32
  start-page: 668
  year: 2015
  end-page: 678
  article-title: Epidemiology of frequently occurring skin diseases in italian children from 2006 to 2012: a retrospective, population‐based study
  publication-title: Pediatr Dermatol
– volume: 69
  start-page: 868
  year: 2014
  end-page: 887
  article-title: The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
  publication-title: Allergy
– volume: 9
  start-page: 212
  year: 2017
  end-page: 219
  article-title: Prevalence and risk factors of urticaria with a focus on chronic urticaria in children
  publication-title: Allergy Asthma Immunol Res
– volume: 29
  start-page: 16
  issue: Suppl 3
  year: 2015
  end-page: 32
  article-title: Management and treatment of chronic urticaria (CU)
  publication-title: J Eur Acad Dermatol Venereol
– volume: 155
  start-page: 145
  year: 2006
  end-page: 151
  article-title: A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases
  publication-title: Br J Dermatol
– year: 2017
– volume: 17
  start-page: 1131
  year: 2016
  end-page: 1139
  article-title: Current and future therapies for treating chronic spontaneous urticaria
  publication-title: Expert Opin Pharmacother
– volume: 104
  start-page: 369
  year: 1981
  end-page: 381
  article-title: Recurrent urticaria: clinical investigation of 330 patients
  publication-title: Br J Dermatol
– volume: 12
  start-page: 485
  year: 2012
  end-page: 490
  article-title: Childhood urticaria
  publication-title: Curr Opin Allergy Clin Immunol
– ident: e_1_2_7_6_1
  doi: 10.1111/jdv.13198
– ident: e_1_2_7_12_1
  doi: 10.1517/14656566.2016.1159298
– ident: e_1_2_7_23_1
  doi: 10.1111/j.1365-2230.2010.03840.x
– ident: e_1_2_7_7_1
  doi: 10.1111/j.1365-2133.2006.07185.x
– ident: e_1_2_7_26_1
  doi: 10.1111/j.1445-5994.2008.01719.x
– ident: e_1_2_7_20_1
  doi: 10.1067/mjd.2001.116217
– ident: e_1_2_7_13_1
  doi: 10.1111/pde.12568
– volume: 69
  start-page: 61
  year: 1992
  ident: e_1_2_7_18_1
  article-title: Etiologic factors in childhood chronic urticaria
  publication-title: Ann Allergy
– ident: e_1_2_7_4_1
  doi: 10.1097/ACI.0b013e3283574cb3
– ident: e_1_2_7_5_1
  doi: 10.1111/j.1399-3038.2010.01120.x
– volume: 19
  start-page: 21
  issue: 2
  year: 2009
  ident: e_1_2_7_8_1
  article-title: Epidemiology, healthcare, resources, use and clinical features of different types of urticaria
  publication-title: J Investig Allergol Clin Immunol
– ident: e_1_2_7_3_1
  doi: 10.1111/all.12313
– ident: e_1_2_7_16_1
– ident: e_1_2_7_19_1
  doi: 10.1111/j.1365-2133.1981.tb15306.x
– ident: e_1_2_7_11_1
  doi: 10.1001/jamadermatol.2017.3183
– ident: e_1_2_7_25_1
  doi: 10.1164/rccm.2204012
– ident: e_1_2_7_2_1
  doi: 10.1111/j.1398-9995.2010.02496.x
– ident: e_1_2_7_24_1
– ident: e_1_2_7_17_1
  doi: 10.4168/aair.2017.9.3.212
– ident: e_1_2_7_15_1
  doi: 10.1016/j.jaci.2004.07.042
– ident: e_1_2_7_10_1
  doi: 10.4168/aair.2017.9.3.189
– volume: 62
  start-page: 421
  year: 1989
  ident: e_1_2_7_21_1
  article-title: The natural history and response to therapy of chronic urticaria and angioedema
  publication-title: Ann Allergy
– volume: 17
  start-page: 28
  issue: 2
  year: 2007
  ident: e_1_2_7_9_1
  article-title: Use of antihistamines in pediatrics
  publication-title: J Investig Allergol Clin Immunol
– ident: e_1_2_7_14_1
  doi: 10.1007/s40257-015-0134-8
– ident: e_1_2_7_22_1
  doi: 10.1111/j.1398-9995.2004.00473.x
– volume: 17
  start-page: 437
  year: 2002
  ident: e_1_2_7_27_1
  article-title: H1‐antihistamines in children
  publication-title: Clin Allergy Immunol
– reference: 30054937 - Pediatr Allergy Immunol. 2018 Sep;29(6):670-671
– reference: 29974980 - Pediatr Allergy Immunol. 2018 Sep;29(6):669-670
SSID ssj0017361
Score 2.4900577
Snippet Background Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are...
Data on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are scarce. This...
BackgroundData on the prevalence and disease management of chronic urticaria (CU) and chronic spontaneous urticaria (CSU) in the pediatric population are...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 630
SubjectTerms Angioedema
Antihistamines
chronic spontaneous urticaria
chronic urticaria
Corticosteroids
Dermatitis
Disease management
Edema
Europe
Patients
pediatric
Pediatrics
Population studies
prevalence
Steroid hormones
treatment patterns
Urticaria
Title Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpai.12910
https://www.ncbi.nlm.nih.gov/pubmed/29679413
https://www.proquest.com/docview/2091573007
https://www.proquest.com/docview/2028946346
Volume 29
WOSCitedRecordID wos000442500100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1399-3038
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017361
  issn: 0905-6157
  databaseCode: DRFUL
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS9xAEB9ERfrSVuvHWSur9MGXyGU_sgl9kraHgsohCvdk2Gx24UByx8Xr3-_M5gOPWhD6EpZkkl1mdzIzuzO_AfiuUInZMuZRqWi3SkgVZbwwkeWxV95LJXgRik3o29t0MsnGa_Cjy4Vp8CH6DTeSjPC_JgE3Rf1KyOdmeo7KitKrNuJYpFS3gctxf4SgRQBLHWZDhf6R0i2sEIXx9K-uKqO_LMxVgzVonNGn_xrrZ_jYGprsolkZ27Dmqh3YummP0r_AI4E3mZByxExVsi5FktlVCGc283grIOgyCqdFY9LNljVb0ofR0TZsWrF5V_CDtTit9S48jH7f_7yM2mILkSUQvihOkszH2ttUc4NyrEstS8qS1dyLVHpvpbVuqLgtuNYudal3WpiMDExJzT1Yr2aVOwCmkVJ5bYpYJ3JoiqwUFG7OLa4LZ0s_gLOO67ltkcipIMZT3nkkyK888GsApz3pvIHfeIvoqJu6vJXAOudoCCkC49cDOOkfo-zQgUjDKaRBd1MmQiYD2G-mvO-FZwn-qmKBgw0z--_u8_HFVWgcvp_0K3xAyyttgtWOYP15sXTfYNP-eZ7Wi-OwkPGqJ-kxbPy6Gz1cvwBHyPcL
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB9ExfPl_Dg_9vyKcg--VLZp0rTgi5wuiusiouCTJU0TWJDu4rr-_c6kH7iocHBvoZ02YTKTzCQzvwH4I3ETM0XIg0LSaVUkZJDyXAeGh046J2TEc19sQg0GyeNjejsHp00uTIUP0R64kWb49ZoUnA6kP2j5WA9PcLei_KoFgWKE8r1wftd76Le3CCryeKndtCvRRZKqRhaiSJ7249n96JOROWuz-k2nt_J_w12Fn7Wxyc4q6ViDOVuuw9JNfZ3-C54IwEn7tCOmy4I1aZLMzMI4s5HDRx5Fl1FILRqUdjSdsCn9GJ1tzYYlGzdFP1iN1TrZgIfexf3fy6AuuBAYAuILwjhOXaicSRTXqMuqUKKgTFnFXZQI54wwxnYlNzlXyiY2cVZFOiUjU1BzE-bLUWm3gSmklE7pPFSx6Oo8LSIKOecGZcOawnXguGF7Zmo0ciqK8Zw1XgnyK_P86sBRSzquIDi-Itpt5i6rtXCScTSGJAHyqw4ctq9Rf-hSpOIU0qDLieIj4g5sVXPe9sLTGJerMMLB-qn9vvvs9uzKN37_O-kB_Li8v-ln_avB9Q4soyWWVMFruzD_-jK1e7Bo3l6Hk5f9Wq7fAQFq-gk
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED9CUsJeun5sa9asU8ce9uIRy5JlQ1_CstCwNITSQp9mZFmCwHBC0-zv3538wUI3GOxN2GdLnHS6O-nudwAfJSoxU4Q8KCSdVkVCBinPdWB46KRzQkY898Um1GKRPDykyw5cNbkwFT5Ee-BGkuH3axJwuyncb1K-0avPqK0ov6onqIhMF3qT2-n9vL1FUJHHSx2lI4kuklQ1shBF8rQf7-ujZ0bmvs3qlc705f8N9wgOa2OTjavVcQwdW55A_6a-Tj-F7wTgpH3aEdNlwZo0SWb2YZzZ2uEjj6LLKKQWDUq73m3Zjn6MzrZmq5JtmqIfrMZq3b6C--nXuy_XQV1wITAExBeEcZy6UDmTKK5RllWhREGZsoq7KBHOGWGMHUlucq6UTWzirIp0SkamoOZr6Jbr0p4BU0gpndJ5qGIx0nlaRBRyzg2uDWsKN4BPDdszU6ORU1GMH1njlSC_Ms-vAXxoSTcVBMefiIbN3GW1FG4zjsaQJEB-NYDL9jXKD12KVJxCGnQ5RRyJeABvqjlve-FpjNtVGOFg_dT-vftsOZ75xtt_J30P_eVkms1ni2_n8AINsaSKXRtC9-lxZ9_Bgfn5tNo-XtTL-heVQPmE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+and+clinical+characteristics+of+chronic+spontaneous+urticaria+in+pediatric+patients&rft.jtitle=Pediatric+allergy+and+immunology&rft.au=Balp%2C+Maria%E2%80%90Magdalena&rft.au=Weller%2C+Karsten&rft.au=Carboni%2C+Veruska&rft.au=Chirilov%2C+Alexandra&rft.date=2018-09-01&rft.issn=0905-6157&rft.eissn=1399-3038&rft.volume=29&rft.issue=6&rft.spage=630&rft.epage=636&rft_id=info:doi/10.1111%2Fpai.12910&rft.externalDBID=10.1111%252Fpai.12910&rft.externalDocID=PAI12910
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0905-6157&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0905-6157&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0905-6157&client=summon